Artigo de periodico

Drug repurposing in chagas disease: chloroquine potentiates benznidazole activity against Trypanosoma cruzi In vitro and in vivo (2022)

• Authors:
  • Pandey, Ramendra Pati
  • Nascimento, Marilda Savoia
  • Franco, Caio Haddad
  • Bortoluci, Karina - Universidade Federal de São Paulo (UNIFESP)
  • Silva, Marcelo Nunes da
  • Zingales, Bianca
  • Gibald, Daniel
  • Barrios, Leda Castaño
  • Vieira, Joseli Lannes
  • Cariste, Leonardo Moro
  • Vasconcelos, Jose Ronnie
  • Moraes, Carolina Borsoi
  • Freitas Junior, Lucio H
  • Kalil Filho, Jorge Elias
  • Alcântara, Laura
  • Cunha Neto, Edecio
• USP affiliated authors: NASCIMENTO, MARILDA SAVOIA - FM ; SILVA, MARCELO NUNES - IQ ; ZINGALES, BIANCA SILVANA - IQ ; KALIL FILHO, JORGE ELIAS - FM ; CUNHA NETO, EDECIO - FM
• Unidades: FM; IQ
• DOI: 10.1128/aac.00284-22
• Subjects: DOENÇA DE CHAGAS; MEDICAMENTO
• Agências de fomento:
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
    Processo FAPESP: 2014/50708-2
  • Financiamento CNPq
  • Financiamento FAPERJ
• Language: Inglês
• Imprenta:
  • Publisher place: Washington
  • Date published: 2022
• Source:
  • Título do periódico: Antimicrobial Agents and Chemotherapy
  • ISSN: 0066-4804
  • Volume/Número/Paginação/Ano: v. 66, n. 11, p. 1-17, art. e0028422, 2022

Informações sobre o DOI: 10.1128/aac.00284-22 (Fonte: oaDOI API)
• Este periódico é de assinatura
• Este artigo é de acesso aberto
• URL de acesso aberto
• Cor do Acesso Aberto: green

---

Download do texto completo

Tipo	Nome	Link
	3106779.pdf	Direct link

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  PANDEY, Ramendra Pati et al. Drug repurposing in chagas disease: chloroquine potentiates benznidazole activity against Trypanosoma cruzi In vitro and in vivo. Antimicrobial Agents and Chemotherapy, v. 66, n. 11, p. 1-17, 2022Tradução . . Disponível em: https://doi.org/10.1128/aac.00284-22. Acesso em: 20 abr. 2024.

• APA

  Pandey, R. P., Nascimento, M. S., Franco, C. H., Bortoluci, K., Silva, M. N. da, Zingales, B., et al. (2022). Drug repurposing in chagas disease: chloroquine potentiates benznidazole activity against Trypanosoma cruzi In vitro and in vivo. Antimicrobial Agents and Chemotherapy, 66( 11), 1-17. doi:10.1128/aac.00284-22

• NLM

  Pandey RP, Nascimento MS, Franco CH, Bortoluci K, Silva MN da, Zingales B, Gibald D, Barrios LC, Vieira JL, Cariste LM, Vasconcelos JR, Moraes CB, Freitas Junior LH, Kalil Filho JE, Alcântara L, Cunha Neto E. Drug repurposing in chagas disease: chloroquine potentiates benznidazole activity against Trypanosoma cruzi In vitro and in vivo [Internet]. Antimicrobial Agents and Chemotherapy. 2022 ; 66( 11): 1-17.[citado 2024 abr. 20 ] Available from: https://doi.org/10.1128/aac.00284-22

• Vancouver

  Pandey RP, Nascimento MS, Franco CH, Bortoluci K, Silva MN da, Zingales B, Gibald D, Barrios LC, Vieira JL, Cariste LM, Vasconcelos JR, Moraes CB, Freitas Junior LH, Kalil Filho JE, Alcântara L, Cunha Neto E. Drug repurposing in chagas disease: chloroquine potentiates benznidazole activity against Trypanosoma cruzi In vitro and in vivo [Internet]. Antimicrobial Agents and Chemotherapy. 2022 ; 66( 11): 1-17.[citado 2024 abr. 20 ] Available from: https://doi.org/10.1128/aac.00284-22

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease
• Modulation of class II MHC expression in human cells infected with Trypanosoma cruzi
• Evidence for T Cell help in the IgG response against tandemly repetitive Trypanosoma cruzi B13 protein in chronic Chagas disease patients
• Anticorpos anti vimentina em soro de pacientes com doença de Chagas
• T-cell molecular mimicry in Chagas disease: identification and partial structural analysis of multiple cross-reactive epitopes between Trypanosoma cruzi B13 and cardiac myosin heavy chain
• Novas estratégias de vacinas
• HIV CD4 based vaccine increases CD8 cell responses andconfers protection against challenge with recombinant vaccinia enconding HIV gag-pol proteins
• Protease inhibitors-induced mutations do not impair the in silico binding prediction of HIV-1 protease sequences to HLA-DR molecules
• Novel HIV-1 multiepitopic and multiallelic vaccine formulations elicit strong CD4+ and CD8+ immune responses in BALB/C and HLA class-II transgenic mice
• Immunogenecity of a DNA vaccine containing multiple HLA-DR binding, conserved M group HIV-1 epitopes in Balc/C mice